Related Experiment Videos
Prolonged paralysis after treatment with neuromuscular junction blocking agents.
J L Gooch1, M R Suchyta, J M Balbierz
1Department of Physical Medicine and Rehabilitation, University of Utah Health Sciences Center, Salt Lake City.
Critical Care Medicine
|September 1, 1991
Summary
Critically ill patients treated with neuromuscular junction blocking agents may develop prolonged weakness. This neurogenic atrophy can significantly delay recovery and ventilator weaning, necessitating careful drug use.
Area of Science:
- Neurology
- Critical Care Medicine
- Pharmacology
Background:
- Prolonged paralysis following neuromuscular junction blocking agent (NMBA) use has been reported in critically ill patients.
- This study aimed to further characterize patients experiencing prolonged weakness after NMBA treatment.
Observation:
- A cohort of critically ill patients with diverse diagnoses developed severe weakness post-NMBA discontinuation.
- Patients exhibited pronounced weakness without sensory deficits.
- Electrodiagnostic studies and muscle biopsies indicated impaired neuromuscular transmission.
Findings:
- No single underlying disorder or medication was common to all affected patients, despite some having pre-existing conditions or taking interacting drugs.
- Recovery of muscle strength was protracted, often taking months.
- Mechanical ventilator weaning was frequently delayed in these patients.
Implications:
- The findings suggest that neuromuscular junction blocking agents may contribute to neurogenic atrophy.
- Caution is advised when administering these agents to critically ill individuals.
- Further research into the mechanisms and management of NMBA-induced weakness is warranted.